YWYan Wang

Yan Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yan Wang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Andre J. Jeyarajan

    Liver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

    1 shared publication
  • Chuanwu Zhu

    Department of Hepatology The Fifth People's Hospital of Suzhou Suzhou China

    1 shared publication
  • Jacinta A. Holmes

    Department of Gastroenterology St. Vincent's Hospital Fitzroy Victoria Australia

    1 shared publication
  • Ming Yue

    Department of Infectious Diseases The First Affiliated Hospital of Nanjing Medical University Nanjing China

    1 shared publication
  • Peng Huang

    Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China

    1 shared publication
  • Raymond T. Chung

    Liver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

    1 shared publication

Latest Publications

  • The risk of hepatitis C virus recurrence in hepatitis C virus‐infected patients treated with direct‐acting antivirals after achieving a sustained virological response: A comprehensive analysis

    by Peng Huang, Yan Wang, Ming Yue, Zhijun Ge, Xueshan Xia, Andre J. Jeyarajan, Jacinta A. Holmes, Rongbin Yu, Chuanwu Zhu, Sheng Yang, et al.

    Background & Aims: The risk for hepatitis C virus (HCV) recurrence persists after HCV eradication with direct‐acting antivirals (DAAs), particularly in patients with ongoing high‐risk behaviours. Our aim was to assess the risk of HCV recurrence (late relapse and/or reinfection) post‐sustained virological response (SVR).Methods: We searched the literature for studies reporting HCV recurrence rates post‐SVR in PubMed, Web of Science and the Cochrane Library. Identified publications were divided into groups based on patient risk for HCV reinfection: low‐risk HCV mono‐infection, high‐risk HCV mono‐infection and a human immunodeficiency virus (HIV)/HCV coinfection. The HCV recurrence rate for each study was calculated by using events divided by the person‐years of follow‐up (PYFU). HCV recurrence was defined as confirmed, detectable HCV RNA post‐SVR.Results: In the 16 studies of low‐risk patients, the pooled recurrence rate was 0.89/1000 PYFU (95% confidence interval [CI], 0.16‐2.03). For the 19 studies of high‐risk patients, the pooled recurrence rate was 29.37/1000 PYFU (95% CI, 15.54‐46.91). For the eight studies of HIV/HCV‐coinfected patients, the pooled recurrence rate was 23.25/1000 PYFU (95% CI, 4.24‐53.39). The higher pooled estimates of recurrence in the high‐risk and HIV/HCV‐coinfected populations were predominantly driven by an increase in reinfection rather than late relapse.Conclusions: The HCV recurrence risk after achieving SVR with all‐oral DAAs therapy is low, and the risk of HCV recurrence in high‐risk and HIV/HCV‐coinfected populations was driven by an increase in reinfection rather than late relapse.